MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 14.1%

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIAGet Free Report) dropped 14.1% on Wednesday . The stock traded as low as $3.05 and last traded at $3.23. Approximately 692,035 shares changed hands during mid-day trading, an increase of 71% from the average daily volume of 405,218 shares. The stock had previously closed at $3.76.

MAIA Biotechnology Trading Up 16.3 %

The company has a market cap of $84.30 million, a P/E ratio of -2.44 and a beta of 0.46.

MAIA Biotechnology (NYSEAMERICAN:MAIAGet Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.13). Research analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Stan Smith acquired 170,940 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were purchased at an average price of $1.17 per share, for a total transaction of $199,999.80. Following the acquisition, the director now owns 857,568 shares in the company, valued at $1,003,354.56. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other MAIA Biotechnology news, Director Ngar Yee Louie bought 19,665 shares of MAIA Biotechnology stock in a transaction dated Thursday, April 25th. The stock was bought at an average price of $2.03 per share, for a total transaction of $39,919.95. Following the completion of the acquisition, the director now directly owns 1,167,189 shares of the company’s stock, valued at $2,369,393.67. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Stan Smith purchased 170,940 shares of the stock in a transaction dated Thursday, March 14th. The shares were acquired at an average price of $1.17 per share, for a total transaction of $199,999.80. Following the acquisition, the director now directly owns 857,568 shares of the company’s stock, valued at approximately $1,003,354.56. The disclosure for this purchase can be found here. Insiders own 36.98% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in MAIA Biotechnology stock. Virtu Financial LLC bought a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIAFree Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 32,487 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned about 0.15% of MAIA Biotechnology at the end of the most recent reporting period. 5.65% of the stock is owned by hedge funds and other institutional investors.

About MAIA Biotechnology

(Get Free Report)

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.

Read More

Receive News & Ratings for MAIA Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAIA Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.